- The 3.25 million units of stocks and warrants of Allergan LigandRetinoid Therapeutics that have traded publicly have been separated into their component parts and have traded separately since June 3. This relates to the formation of the firm by Allergan and Ligand, and an offering made by ALRT on June 3, 1995. The ALRT callable common stock and the Ligand warrants will trade separately on the Nasdaq. Ligand has the option to acquire the callable common stock of ALRT after June 3, 1997, at which point Allergan has the right to acquire an undivided one-half interest in ALRT technology, and 50% of all other ALRT assets. Ligand's option will expire on June 3, 2000 unless earlier triggered by ALRT's available funds falling below the benchmark of $10 million.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze